Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | The impact of germline mutations on AML managment

Lucy Godley • 1 Jul 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia

Lucy Godley, MD, PhD, University of Chicago, Chicago, IL, discusses how the distinction between somatic and germline mutations has a significant impact on the patient’s management as well as important implications for their family members. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lucy Godley

6:56
Germline predisposition to AML
Lucy Godley • 1 Jul 2020
2:27
Germline predisposition to myeloid malignancies: emerging research
Lucy Godley • 1 Jul 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals